| David M. Holtzman | |
|---|---|
| Photo placeholder | |
| Affiliations | Washington University in St. Louis |
| Country | USA |
| H-index | 200 |
| ORCID | 0000-0001-6390-095X |
| Research Focus | Alzheimer's Disease |
| Mechanisms | Amyloid, APOE, Sleep |
David M. Holtzman is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
David M. Holtzman is a leading researcher in the field of neurodegenerative diseases, affiliated with Washington University in St. Louis. Their research focuses on Amyloid, APOE, Sleep, with particular emphasis on Alzheimer's Disease. With an h-index of 200, Holtzman is among the most cited researchers in the neuroscience field.
Holtzman's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease.
Dr. David Holtzman is a renowned neurologist and neuroscientist whose research has fundamentally advanced our understanding of Alzheimer's disease pathogenesis. His work at Washington University has focused on the role of amyloid, APOE, and sleep in neurodegenerative processes.
Amyloid-beta Metabolism: Dr. Holtzman's laboratory has made seminal discoveries about how amyloid-beta is produced, cleared, and aggregated in the brain, revealing key pathways involved in Alzheimer's disease pathogenesis.
APOE and Lipid Metabolism: His research has elucidated the critical role of APOE (particularly the APOE4 allele) in modulating Alzheimer's disease risk through effects on amyloid clearance, neuroinflammation, and lipid metabolism.
Sleep and Neurodegeneration: Dr. Holtzman has pioneered research demonstrating bidirectional relationships between sleep disruption and Alzheimer's disease pathology, showing how poor sleep can increase amyloid accumulation.
CSF and Blood Biomarkers: His work has contributed to developing cerebrospinal fluid and plasma biomarkers for Alzheimer's disease diagnosis and monitoring.
Genetic Risk Factors: Research on how genetic variants modify Alzheimer's disease risk and progression.
Dr. Holtzman has made groundbreaking contributions to Alzheimer's disease research:
Dominantly Inherited Alzheimer Network (DIAN): Leading investigator in this international study of individuals with genetic forms of Alzheimer's disease.
Alzheimer's Disease Neuroimaging Initiative (ADNI): Key contributor to this landmark study characterizing Alzheimer's disease biomarkers.
Therapeutic Development: His research has informed the development of anti-amyloid and anti-tau therapeutic strategies currently in clinical trials.
Sleep Research: Pioneered understanding of how sleep disturbances contribute to Alzheimer's disease pathogenesis.
Dr. Holtzman's research has had significant clinical implications:
With over 480 publications, Dr. Holtzman has authored influential papers on:
Dr. Holtzman has trained many researchers who have become leaders in Alzheimer's disease and sleep research. His lab has hosted postdoctoral fellows, graduate students, and clinical researchers interested in the intersection of sleep and neurodegeneration.
Future research directions in the Holtzman lab include:
Dr. Holtzman collaborates with multiple research groups:
The study of David M. Holtzman has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.